Addex Therapeutics Ltd. (NASDAQ:ADXN) Chief Medical Officer and Director Roger Mills filed a Form 4 on November 13, 2026, disclosing the acquisition of stock options on November 11, 2026.
Key Highlights
- Transaction: Roger Mills acquired 942,854 stock options (right to buy) on November 11, 2026, with transaction code A.
- Exercise price: $0.026 per option, converted from CHF to USD at a rate of $1.1995 per CHF 1.00 as of November 11, 2026.
- Price paid: $0 for the derivative securities at the time of grant.
- Vesting schedule: Options vest in equal monthly installments over a 4-year period beginning at the exercisable date of November 11, 2026.
- Expiration: Options expire on November 10, 2036.
- Post-transaction holdings: Mills beneficially owns 992,854 derivative securities following this transaction, held directly.
- Underlying security: Each stock option grants the right to purchase one ADXN share listed on SIX Swiss Exchange.
Addex Therapeutics CMO Roger Mills Receives Stock Option Grant
According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 13, 2026, Roger Mills, who serves as both a Director and Chief Medical Officer of Addex Therapeutics Ltd., acquired 942,854 stock options on November 11, 2026. The filing lists the transaction code as A, indicating an acquisition. Mills is based in Geneva, Switzerland, and signed the filing through Lenaic Nathanael Teyssedou by power of attorney.
The filing discloses that the exercise price of $0.026 per option is reported in U.S. dollars and reflects a conversion from CHF to USD at an exchange rate of $1.1995 per CHF 1.00 as of November 11, 2026. The price of the derivative security at the time of the grant is reported as $0. Each stock option grants the right to purchase one ADXN share listed on the SIX Swiss Exchange.
According to the filing's explanation of responses, the stock options vest in equal monthly installments over a 4-year period beginning at the exercisable date of November 11, 2026, and expire on November 10, 2036. Following the reported transaction, Mills beneficially owns 992,854 derivative securities in total, held directly. No non-derivative securities transactions were reported in Table I of this filing.
What Was Disclosed
The filing reports the grant of 942,854 stock options to Addex Therapeutics Chief Medical Officer and Director Roger Mills on November 11, 2026, exercisable at $0.026 per share, vesting monthly over four years, and expiring November 10, 2036.




Please wait processing your request...